Darunavir: An overview of an HIV protease inhibitor developed to overcome drug resistance

Babafemi O. Taiwo*, Charles B. Hicks

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Darunavir (TMC114) is a second-generation, sulfonamide, nonpeptidic protease inhibitor (PI) with a unique, flexible, 3-dimensional structure that contributes to its high potency and slow selection of resistant virus. Darunavir has to be coadministered with low-dose ritonavir and food to optimize its pharmacokinetics. Ritonavir-boosted darunavir is effective in many heavily pretreated patients, including those with multiple PI resistance mutations. In vitro, the coexistence of numerous PI mutations was required for its virological potency to be significantly reduced. Preliminary findings suggest that it is active against some tipranavir-resistant strains.

Original languageEnglish (US)
Pages (from-to)151-156+159-160+161
JournalAIDS Reader
Issue number3
StatePublished - Mar 1 2007


  • Antiretroviral therapy
  • Darunavir
  • Drug resistance
  • Protease inhibitors
  • Ritonavir boosting

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'Darunavir: An overview of an HIV protease inhibitor developed to overcome drug resistance'. Together they form a unique fingerprint.

Cite this